ATE110957T1 - Pharmazeutische behandlung einer augenentwicklung. - Google Patents

Pharmazeutische behandlung einer augenentwicklung.

Info

Publication number
ATE110957T1
ATE110957T1 AT89907488T AT89907488T ATE110957T1 AT E110957 T1 ATE110957 T1 AT E110957T1 AT 89907488 T AT89907488 T AT 89907488T AT 89907488 T AT89907488 T AT 89907488T AT E110957 T1 ATE110957 T1 AT E110957T1
Authority
AT
Austria
Prior art keywords
pharmaceutical treatment
eye development
eye
development
controlling
Prior art date
Application number
AT89907488T
Other languages
English (en)
Inventor
Richard A Stone
Alan M Laties
Paul M Iuvone
Original Assignee
Univ Pennsylvania
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Univ Emory filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE110957T1 publication Critical patent/ATE110957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT89907488T 1988-06-03 1989-06-01 Pharmazeutische behandlung einer augenentwicklung. ATE110957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20222088A 1988-06-03 1988-06-03
US34294289A 1989-04-25 1989-04-25

Publications (1)

Publication Number Publication Date
ATE110957T1 true ATE110957T1 (de) 1994-09-15

Family

ID=26897480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89907488T ATE110957T1 (de) 1988-06-03 1989-06-01 Pharmazeutische behandlung einer augenentwicklung.

Country Status (7)

Country Link
US (2) US5284843A (de)
EP (1) EP0422068B1 (de)
JP (1) JP2741624B2 (de)
AT (1) ATE110957T1 (de)
CA (1) CA1336490C (de)
DE (1) DE68918099T2 (de)
WO (1) WO1989011854A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
ATE147626T1 (de) * 1989-06-21 1997-02-15 Univ Pennsylvania Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth
US5461052A (en) * 1993-04-30 1995-10-24 The Trustees Of The University Of Pennsylvania Prevention of myopia by tricyclic compounds
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
EP0834308A1 (de) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin
US5744468A (en) * 1996-10-23 1998-04-28 Tong-Ho Lin Hypotensive intraocular pressure activity of clozapine and sulpiride
US20030096831A1 (en) * 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
WO2001083714A2 (en) * 2000-05-02 2001-11-08 Central Institute For The Deaf Composition and methods for treating photoreceptor degeneration
EP1397132A4 (de) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I Ophthalmisches pirenzepin-gel
FI20075498A7 (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
JP6382993B2 (ja) * 2013-09-30 2018-08-29 オリオン コーポレーション 嘔吐を誘導するための獣医学的方法
JP6085722B2 (ja) * 2014-06-03 2017-02-22 株式会社坪田ラボ 近視予防物品及び近視予防セット
US10823982B2 (en) 2014-06-03 2020-11-03 Tsubota Laboratory, Inc. Myopia treatment device
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
JP6508536B2 (ja) * 2016-05-19 2019-05-08 株式会社小出光学 眼球模型群セット
IT201800005599A1 (it) * 2018-05-22 2019-11-22 Lente a contatto morbida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
CA1336490C (en) * 1988-06-03 1995-08-01 Paul Michael Iuvone Pharmacological treatment of ocular development
US5122522A (en) * 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
ATE147626T1 (de) * 1989-06-21 1997-02-15 Univ Pennsylvania Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
US5360801A (en) * 1989-06-21 1994-11-01 The Trustees Of The University Of Pennsylvania Pharmacological stimulation of eye growth
US5055302A (en) * 1990-02-22 1991-10-08 Trustees Of The University Of Pennsylvania Neuropeptide control of ocular growth
US5385939A (en) * 1993-04-30 1995-01-31 The Trustees Of The University Of Pennsylvania GABA-ergic modulation of eye growth

Also Published As

Publication number Publication date
US5571823A (en) 1996-11-05
DE68918099D1 (de) 1994-10-13
EP0422068A1 (de) 1991-04-17
JP2741624B2 (ja) 1998-04-22
US5284843A (en) 1994-02-08
WO1989011854A1 (en) 1989-12-14
CA1336490C (en) 1995-08-01
EP0422068A4 (en) 1992-01-08
DE68918099T2 (de) 1995-01-05
HK1007680A1 (en) 1999-04-23
EP0422068B1 (de) 1994-09-07
JPH06502839A (ja) 1994-03-31

Similar Documents

Publication Publication Date Title
ATE110957T1 (de) Pharmazeutische behandlung einer augenentwicklung.
ATE169219T1 (de) Behandlung von katarakt mit 15-keto- prostaglandinderivaten
NO904694D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
ATE69376T1 (de) Haarwuchsmittel.
FI920601A0 (fi) Tvaofasig anordning foer transdermal dosering av laekemedel.
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DE69010251D1 (de) Dentale Einheit zur Behandlung eines Wurzelkanals.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
IT1238825B (it) Dispositivo per la correzione chirurgica dell'ametropia.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO902710L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive r(-) 3-kinuklidinol-derivater.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
NO884176L (no) Fremgangsmaate for fremstilling av terapeutisk aktive amidinoderivater.
DK707988A (da) Fremgangsmaade til at haemme virus
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE59107111D1 (de) 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
AU4246189A (en) Medicament for the treatment of diseases caused by retroviruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee